Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring

Definitions

• the present invention relates to a process for the regioselective synthesis of a compound of formula I,
• RO, R1 , R2, R3, R4, R5, R6, A1 , A2, A3, A4, Q, T and J have the meanings indicated below and are useful as intermediates for the preparation of valuable pharmaceutically active ingredients.
• the present invention relates to a direct transition metal catalyzed process for the preparation of a variety of multifunctional substituted N-aminoindoles of formula I from 2-halo-phenylacetylenes or (2-sulfonato)phenylacetylenes and N,N-disubstituted hydrazines.
• Indole skeleton is found in numerous natural products as well as in the essential amino acid tryptophan and thus also in proteins. Indole derivatives display a vide variety of biological activities and can thus be regarded as a privileged structure in pharmaceutical research.
• indole scaffold ability of the indole scaffold to mediate an interaction with a variety of biological targets, is well-documented by a number of reports on the observed biological activity, as well as by the fact that many marketed drugs contain this heterocycle (J. A. Joule, in Science of Synthesis 2000, 10, 361ff and references therein).
• examples of marketed drugs having an indole structural element include the anti-inflammatory indomethacin, the betablocker pindolol, the antimigraine agent sumitriptan and the 5-HT 3 antagonist ondansetron.
• indoles or azaindoles is not limited to the above-mentioned pharmaceutical application and it is well known that indoles can be useful in numerous other applications.
• 1 H-indole-3-acetic acid is used as a plant growth regulator and 3-methyl-indole (skatol) and various other indoles are used as components in perfumes and fragrances.
• N-aminoindoles display various biological activities such as antidepressant (F. Schatz, U. Jahn, T. Wagner-Jauregg, L. Zirngibl, K.
• the present invention provides a direct transition metal catalyzed synthetic route to a wide variety of multifunctional N-aminoindoles of formula I starting from 2-halo- phenylacetylenes or (2-sulfonate)phenylacetylenes of formula Il and N,N-disubstituted hydrazines of formula III.
• the advantages of the provided process are that it comprises a direct, catalytic, mild and versatile method for the synthesis of N-aminoindoles. Since the multi-step reaction proceeds as a one-pot domino reaction sequence using only a single catalyst, the process is very time- and cost-effective as well as being environmentally benign. Furthermore, the reaction conditions are compatible with a broad range of functional groups and a large variety of starting materials ensuring the generality of the reaction.
• A1 , A2, A3 and A4 are independently from each other selected from a carbon or a nitrogen atom to form together with the two carbon atoms in formula I a stable aromatic or heteroaromatic ring;
• Q is a covalent bond, -(C-
• alkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;
• alkenylene is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, -(C2-C6)-alkynylene, wherein alkynylene is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, -(C-3-C8)-cycloalkyl, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;
• aryl is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by R 13;
• heteroaryl is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by R13;
• T is a covalent bond
• -Ce)-alkylene wherein alkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by R14; -(C3-C-8)-cycloalkyl, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14; -(C6-C-
• R13 tri- or four times substituted independently of one another by R13, j) a 3- to 7-membered cyclic residue, containing 1 , 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by R13, k) -0-CF 3 , I) -O-(C-
• A2, A3 or A4 are nitrogen atom, or
• R1 and R2, R2 and R3 or R3 and R4 form together with the atoms which they are attached to a 5- or 8-membered ring, containing up to 0, 1 , 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said ring is unsubstituted or substituted one, two, three or four times by R14,
• R10 is hydrogen atom, -(C-
• R11 and R12 are independently of one another identical or different and are a) hydrogen atom, b) -(C-
• 4)-heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, R13 is halogen, -NO 2 , -CN, O, -OH, -(C 1 -CeJ-alkyl, -(C-
• aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, -(C4-C-
• R17 and R18 are independently of one another identical or different and are a) hydrogen atom, b) -(CrC ⁇ -alkyl, c) -(C6-Ci4)-aryl- or d) -(C4-
• RO, R1 , R2, R3, R4, A1 , A2, A3, R4 and Q are as defined in formula I and X is Cl, Br, I, triflate, nonaflate, tosylate, alkyl sulfonate or aryl sulfonate, with a compound of formula III or any salts thereof, wherein J 1 T, R5 and R6 are as defined in formula I, in the presence of a transition metal catalyst to give a compound of formula I and optionally the compound of formula I is converted to its physiologically tolerated salt.
• the present invention also relates to a process for the preparation of selected compounds of formula I, wherein A1 , A2, A3 and A4 form together with the two carbon atoms in formula I a benzene, pyrazine, pyridazine, pyridine, pyrimidine, triazine or tetrazine,
• alkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;
• cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14; phenyl, wherein phenyl is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by R13; or -(C4-C-
• -Cg)-alkylene wherein alkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by R14; -(C3-C-6)-cycloalkyl, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14; phenyl, wherein phenyl is unsubstituted or mono-, di-, tri- or four times substituted independently of one another by R13; or -(C4-C-
• a 3- to 7-membered cyclic residue selected from azepine, azetidine, aziridine, azirine, 1 ,4 diazepane, 1 ,2-diazepine, 1 ,3-diazepine, 1 ,4- diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1 ,3- dioxolene, 1 ,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketomorpholine, ketopiperazine, morpholine,
• A2, A3 or A4 are nitrogen atom
• R10 is hydrogen atom, -(C-
• R11 and R12 are independently of one another identical or different and are a) hydrogen atom, b) -(C-
• 4)-heteroaryl, wherein heteroaryl is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, R13 is F, Cl, -CN, O, -OH, -(Ci -C 8 )-alkyl, -(Ci -C 8 )-alkoxy, -CF 3 , phenyloxy-,
• n 1 or 2
• n 1 or 2
• n 1 or 2
• phenyl wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, -(C4-C-
• R17 and R18 are independently of one another identical or different and are a) hydrogen atom, b) -(Ci-C 4 )-alkyl, c) phenyl or d) -(C 4 -C i4)-heteroaryl, wherein heteroaryl is as defined above, and
• X is Cl, Br, I, triflate, nonaflate or tosylate.
• the present invention also relates to a process for the preparation of a compound of formula I, wherein
• A1 , A2, A3 and A4 form together with the two carbon atoms in formula I a benzene or pyridine,
• Q is a covalent bond, methylene, ethylene, phenyl or pyridyl
• J is a covalent bond, methylene, ethylene, phenyl or pyridyl
• T is a covalent bond, methylene, ethylene, phenyl or pyridyl,
• RO, R1 , R2, R3, R4, R5 and R ⁇ are independent of one another identical or different and are a) hydrogen atom, b) F, c) Cl or Br, d) -(C-
• R1 , R2, R3 or R4 are absent in case one or more of A1 ,
• A2, A3 or A4 are nitrogen atom
• R11 is hydrogen atom or -(C-
• X is Cl, Br, I or tosylate.
• the reaction can be performed in a broad range of protic or aprotic solvents, including polar aprotic solvents, or even in some cases without a solvent.
• solvents are: tert-butanol, benzene, toluene, xylene, mesitylene, acetonitrile, propionitrile, tetrahydrofurane, 2-methyl-tetrahydrofurane, N,N-dimethylformamide, N- methylpyrrolidinone, N,N-dimethylacetamide, dimethylsulfoxide, 1 ,2-dimethoxyethane, tert-butylmethylether, triethylamine, diisopropylethylamine or pyridine.
• Preferred is N.N-dimethylacetamide, N,N-dimethylformamide, N-methylpyrrolidinone.
• Most preferred is N,N-dimethylformamide.
• Useful bases for the process of the present invention is a basic organic or inorganic compound that acts as proton acceptor without inhibiting the catalytic activity of the employed transition metal catalyst.
• Suitable classes of such bases are for example carbonates, phosphates, alkoxides, hydroxides, amides, hydrides with a suitable metal as counter ion, or an alkali metal.
• Carbonates and phosphates are the preferred bases in the process of the present invention.
• Potassium carbonate or potassium phosphate and in particular caesium carbonate are the preferred bases.
• the bases can be used in pure form or a mixture of several bases can be used.
• the bases are generally employed in moderate excess based on 2-halo-phenyl- acetylenes or (2-sulfonate)phenylacetylenes of formula II.
• a useful range is a 0.5 to 10 fold excess based on the 2-halo-phenylacetylenes or (2-sulfonate)phenyl-acetylenes of formula II.
• the base may be favourably employed in a 1.4 fold excess based on the 2-halo-phenylacetylenes or (2- sulfonate)phenylacetylenes of formula II.
• reaction mixture in order to generate the hydrazine in situ.
• reaction can also be performed without a base if the hydrazine is used as the corresponding amide prepared by reaction of the hydrazine or hydrazine salt with a strong base.
• the active form of the transition metal catalyst is not known. Therefore, the term
• transition metal catalyst in the present invention shall include any catalytic transition metal and/or catalyst precursor introduced into the reaction vessel and converted in situ into the active form, as well as the active form of the catalyst that promotes any part of the reaction.
• the transition metal catalyst can be used in any amount, but generally 0.00005-90 mol% would be employed. Preferred is the use of 0.01 -20 mol%, and even more preferred is the use of 0.5-10 mol% and most preferably 1-5 mol% of the transition metal catalyst is employed.
• any suitable transition metal catalyst that can mediate the reaction can be employed these include the elements of group 3-12 of the periodic table as well as the lanthanides.
• Preferred transition metals include platinum, palladium, nickel, gold, copper, iron, ruthenium, rhodium and iridium. Even more preferred are nickel and palladium and most preferred palladium.
• the transition metal catalyst can be soluble or insoluble, and the particular source of the transition metal useful in this process can be, but are not limited to: Pd-halides, Pd-halide complexes, Ni-halides, Ni-halide complexes, Pd-phosphine complexes, Ni-phosphine complexes, Pd-alkene complexes, Ni-alkene complexes, Pd-alkanoates, Pd-alkanoate complexes, Pd-acetonates, Ni- alkanoates, Ni-alkanoate complexes, Ni-acetonates, Raney nickel, Pd/C or Ni/C, or polymer supported palladium or nickel species or a mixture thereof.
• Representative examples include, but are not limited to: palladium (II) chloride, palladium (II) bromide, palladium (II) iodide, tris(dibenzylideneacetone)dipalladium(0), palladium (M) acetate, palladium (II) trifluoroacetate, tris(dibenzylideneacetone)dipalladium(0) chloroform adduct, bis(dibenzylideneacetone)palladium (0), bis(triphenylphosphine)palladium (II) chloride, tetrakis(triphenylphosphine)palladium (0), nickel (II) chloride, nickel (II) bromide, nickel (II) iodide, Ni(acac) 2 , Ni(1 ,5-cyclooctadiene) 2 , acetato(2'-di-tert- butylphosphino-1
• the preferred transition metal sources are palladium (II) chloride, palladium (II) bromide, palladium (II) iodide, tris(dibenzylideneacetone)dipalladium(0), palladium (M) acetate, palladium (II) trifluoroacetate, tris(dibenzylideneacetone)dipalladium(0) chloroform adduct, bis(dibenzylideneacetone)palladium (0), bis(triphenylphosphine)- palladium (II) chloride, tetrakis(triphenylphosphine)palladium (0), and even more preferred are palladium (II) chloride, palladium (II) bromide, palladium (II) iodide, tris(dibenzylideneacetone)dipalladium(0).
• the most preferred palladium sources being palladium (II) chloride and tris(di
• the group of ligands useful in this process may be chelating or non-chelating and may include alkyl or aryl phosphines or hybrids thereof e.g. dicyclohexlphenylphosphine, or aryl or alkyl diphosphines or hybrids thereof, diamines, imines, heterocyclic carbenes or hybrids thereof.
• alkyl or aryl phosphines or hybrids thereof e.g. dicyclohexlphenylphosphine, or aryl or alkyl diphosphines or hybrids thereof, diamines, imines, heterocyclic carbenes or hybrids thereof.
• the ligand can be used in its free form or as a salt, e.g. the hydrochloride or tetrafluoroborate salt.
• the ligand can be selected from the following compounds, but are not limited to: tri-te/t-butylphosphine, tri-terf-butylphosphine tetrafluoroborate salt, tricyclohexylphosphine, dicyclohexlphenylphosphine, methyldiphenylphosphine, dimethylphenylphosphine, trimethylphosphine, triethylphosphine, triphenylphosphine, 2-dicyclohexylphosphino-2 l ,4',6 l -triisopropyl-1 ,1 '-biphenyl, 2,2'-bis(di-tert- butylphosphino)-biphenyl, (+/-)-2,2'-bis(diphenylphosphino)-1 ,1 '-binaphthalene, (9,9- dimethyl-9h-xanthene-4,5-d
• Preferred ligands are tri-te/t-butylphosphine, tri-fert-butylphosphine tetrafluoroborate salt, tricyclohexylphosphine, 2-dicyclohexylphosphino-2',4 l ,6 l -triisopropyl-1 ,1 '-biphenyl. More preferred ligands are tri-te/ ⁇ -butylphosphine, tri-tert-butylphosphine tetrafluoro- borate salt, and most preferred is tri-te/ ⁇ -butylphosphine tetrafluoroborate salt.
• tri-terf-butylphosphine or tri-terf-butylphosphine tetrafluoroborate are employed in particular in combination with a palladium source bearing no phosphine itself, like e.g. palladium (II) chloride, palladium (II) bromide, palladium (II) iodide, or tris(dibenzylideneacetone)dipalladium(0).
• a palladium source bearing no phosphine itself like e.g. palladium (II) chloride, palladium (II) bromide, palladium (II) iodide, or tris(dibenzylideneacetone)dipalladium(0).
• the ligand can be used in any amount, but generally 0.00005-90 mol% would be employed. Preferred is the use of 0.01-40 mol%, and even more preferred is the use of 0.5-20 mol% and most preferably 1-10 mol% of the ligand is employed.
• the ratio of the ligand to the transition metal is generally about 1 to 20, preferably about 1-5 and most preferably 2.
• the reaction step is usually carried out in the temperature range 0 °C to 300 0 C, preferably between 25 0 C to 150 0 C, and most preferably between 80 0 C to 130 0 C.
• the reaction is carried out under the exclusion of air and moisture such as under an inert atmosphere like e.g. in an argon or nitrogen atmosphere at atmospheric pressure.
• the reaction time is normally in the range of 2 to 48 hours (h).
• the progress of the reaction may be monitored by methods known to those skilled in the art, like for example thin layer silica gel chromatography, gas chromatography, nuclear magnetic resonance, infrared spectroscopy, and high pressure liquid chromatography combined with ultraviolet detection or mass spectroscopy.
• thin layer silica gel chromatography and high pressure liquid chromatography (HPLC) combined with mass spectroscopy are used.
• isolation and purification procedures useful for the compounds obtained by the process of the present invention are well-known to those skilled in the art, like for example filtration through a celite containing cartridge, aqueous work-up, extraction with organic solvents, distillation, crystallisation, chromatography on silica, and high pressure liquid chromatography on normal phase or reversed phase.
• Preferred methods include, but are not limited to those exemplified.
• Examples of ,,-(Ci-C8)-alkyl” or ,,-(Ci-C8)-alkylene” are alkyl residues containing 1 , 2,
• Examples of ,,-(C2-C6)-alkenyl” or ,,-(C2-C6)-alkenylene” are alkenyls containing 2, 3,
• Examples of or ,,-(C2-C6)-alkynylene are alkynyls containing 2, 3, 4, 5 or 6 carbon atoms, which are e.g. ethynyl, 1-propynyl, 2-propynyl or 2-butynyl.
• cyclic alkyl residues which are cycloalkyl residues containing 3, 4, 5, 6, 7 or 8 ring carbon atoms like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyloheptyl or cyclooctyl, which can also be substituted and/or unsaturated.
• Unsaturated cyclic alkyl groups are e.g. cyclopentenyl or cyclohexenyl.
• alkyl sulfonate is understood as an alkyl residue containing 1 , 2, 3, 4, 5 or 6 carbon atoms substituted by sulfonate. Examples of such residues are methylsulfonate (mesylate), ethylsulfonate, propylsulfonate, butylsulfonate, pentylsulfonate or hexylsulfonate.
• A1 , A2, A3, A4 are independently from each other selected from carbon or nitrogen atoms to form together with the two carbon atoms in formula I a stable aromatic or heteroaromatic ring” refers to a residue which can be derived from compounds such as benzene, pyrazine, pyridazine, pyridine, pyrimidine, triazine or tetrazine.
• -(C6-Ci4)-aryl is understood as meaning aromatic hydrocarbon radicals containing from 6 to 14 carbon atoms in the ring.
• Examples of -(Ce-Ci 4)-aryl radicals are phenyl, naphthyl, for example 1-naphthyl and 2-naphthyl, biphenylyl, for example 2-biphenylyl, 3-biphenylyl and 4-biphenylyl, anthryl or fluorenyl.
• Biphenylyl radicals, naphthyl radicals and, in particular, phenyl radicals are preferred aryl radicals.
• aryl sulfonate is understood as an aryl as defined herein, which is substituted by a sulfonate. Examples of such residues are benzenesulfonate, tosylate, nitrobenzenesulfonate or bromobenzenesulfonate.
• 4)-heteroaryl refers to mono-, di- or tri-ring systems, wherein one or more of the 4 to 14 ring carbon atoms are replaced by one or more heteroatoms such as nitrogen, oxygen or sulphur.
• Examples are acridinyl, azaindole (1 H-pyrrolopyridinyl), azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH- carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5- dihydrooxazolinyl, dioxazolyl, dioxazinyl, 1 ,3-dioxolanyl, 1 ,3-dioxolenyl, 3,3- dioxo[1
• a 3- to 7-membered cyclic residue, containing 1 , 2, 3 or 4 heteroatoms refers to structures of heterocycles, which are e.g. azepine, azetidine, aziridine, azirine, 1 ,4 diazepane, 1 ,2-diazepine, 1 ,3-diazepine, 1 ,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1 ,3-dioxolene, 1 ,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazoie, isoxazoline, isoxazolidine, 2-isoxazoline, ketomorpholine, ketopiperazine, morpholine, 1 ,2-oxa-thiepane
• R1 and R2, R2 and R3 or R3 and R4 form together with the atoms which they are attached to a 5- or 8-membered ring, containing up to 0, 1 , 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen” refers to residues which are e.g.
• azepine azirine, azocane, azocane-2-one, cyloheptyl, cyclohexyl, cyclooctane, cyclooctene, 1 ,4-diazepane, 1 ,2-diazepine, 1 ,3-diazepine, 1 ,4-diazepine, [1 ,2]diazocan-3-one, [1 ,3]diazocan-2-one, [1 ,4]diazocane, dioxazine, dioxazole, [1 ,4]dioxocane, 1 ,3-dioxolane, dioxole, 1 ,3-dioxolene, furan, imidazole, imidazolidine, imidazoline, isothiazole, isothiazolidine, isothiazoline, isothiazole, isoxazoie, isox
• -C3)-fluoroalkyl is a partial or totally fluorinated alkyl-residue, which are e.g. -CF 3 , -CHF 2 , -CH 2 F, -CHF-CF 3 , -CHF-CHF 2 , -CHF-CH 2 F, -CH 2 -CF 3 , -CH 2 -CHF 2 , -CH 2 -CH 2 F, -CF 2 -CF 3 , -CF 2 -CHF 2 , -CF 2 -CH 2 F 1 -CH 2 -CHF-CF 3 , -CH 2 -CHF-CHF 2 , -CH 2 -CHF-CH 2 F, -CH 2 -CH 2 -CF 3 , -CH 2 -CH 2 -CHF 2 , -CH 2 -CH 2 F 1 -CH 2 -CF 2 -CF 3 , -CH 2 -CHF-
• Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine, particularly preferably chlorine or bromine.
• triflate refers to trifluoro-methanesulfonic acid ester or trifluoromethanesulfonate.
• nonaflate refers to 1 ,1 ,2,2,3,3,4,4,4-nonafluoro-1-butanesulfonic acid ester or 1 ,1 ,2,2,3,3,4,4,4-nonafluoro-i-butanesulfonate.
• R1 , R2, R3 or R4 are absent in case one or more of A1 , A2, A3 or A4 are nitrogen atom
• R4 and R3 are absent and R1 and R2 are each a hydrogen atom the residue pyridazine is formed. If R1 and R2 are not each a hydrogen atom but one of the residues specified under b) to x) then a substituted pyridazine residue is formed.
• Optically active carbon atoms present in the compounds of the formula (I) can independently of each other have R configuration or S configuration.
• the compounds of the formula (I) can be present in the form of pure enantiomers or pure diastereomers or in the form of mixtures of enantiomers and/or diastereomers, for example in the form of racemates.
• the present invention relates to pure enantiomers and mixtures of enantiomers as well as to pure diastereomers and mixtures of diastereomers.
• the invention comprises mixtures of two or of more than two stereoisomers of the formula (I), and it comprises all ratios of the stereoisomers in the mixtures.
• the invention relates both to pure E isomers and pure Z isomers and to E/Z mixtures in all ratios.
• the invention also comprises all tautomeric forms of the compounds of the formula (I).
• Diastereomers including E/Z isomers, can be separated into the individual isomers, for example, by chromatography. Racemates can be separated into the two enantiomers by customary methods, for example by chromatography on chiral phases or by resolution, for example by crystallization of diastereomeric salts obtained with optically active acids or bases.
• Stereochemical ⁇ uniform compounds of the formula (I) can also be obtained by employing stereochemical ⁇ uniform starting materials or by using stereoselective reactions.
• the functional groups introduced into the ring system during the N- aminoindole or N-aminoazaindole synthesis can be chemically modified.
• the groups present in the N-aminoindole or N-aminoazaindole ring system can be modified by a variety of reactions and thus the desired residues RO, R1 , R2, R3, R4, R5 and R6 be obtained.
• ester groups present in the benzene nucleus can be hydrolyzed to the corresponding carboxylic acids, which after activation can then be reacted with amines or alcohols under standard conditions.
• Ether groups present at the benzene nucleus for example benzyloxy groups or other easily cleavable ether groups, can be cleaved to give hydroxyl groups which then can be reacted with a variety of agents, for example etherification agents or activating agents allowing replacement of the hydroxyl group by other groups.
• Sulphur-containing groups can be reacted analogously.
• a phenolic hydroxyl group can be attached to a trityl-polystyrene resin, which serves as a protecting group, and the molecule is cleaved from this resin by treatment with TFA at a later stage of the synthesis.
• Physiologically tolerable salts of the compounds of formula I are non-toxic salts that are physiologically acceptable, in particular, pharmaceutically utilizable salts.
• Such salts of compounds of formula I containing acidic groups, for example, a carboxyl group (COOH) include, for example, alkali metal salts or alkaline earth metal salts, such as sodium salts, potassium salts, magnesium salts and calcium salts, as well as salts with physiologically tolerable quaternary ammonium ions, such as tetramethylammonium or tetraethylammonium, and acid addition salts with ammonia and physiologically tolerable organic amines, such as methylamine, dimethylamine, trimethylamine, ethylamine, triethylamine, ethanolamine or tris-(2-hydroxyethyl)amine.
• alkali metal salts or alkaline earth metal salts such as sodium salts, potassium salts, magnesium salts and calcium salts
• Basic groups contained in the compounds of formula I 1 for example, amino groups or guanidino groups, form acid addition salts, for example, with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid, or with organic carboxylic acids and sulfonic acids such as formic acid, acetic acid, oxalic acid, citric acid, lactic acid, malic acid, succinic acid, malonic acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p-toluenesulfonic acid.
• inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid
• organic carboxylic acids and sulfonic acids such as formic acid, acetic acid, oxalic acid, citric acid, lactic acid, malic acid, succinic acid, malonic acid, benzoic acid, maleic acid
• Compounds of the formula I which simultaneously contain a basic group and an acidic group, for example, a guanidino group and a carboxyl group, can also be present as zwitterions (betaines) which are likewise included in the scope of the present invention.
• Salts of compounds of formula I can be obtained by customary methods known to those skilled in the art, for example, by combining a compound of the formula I with an inorganic or organic acid or base in a solvent or dispersant, or from other salts by cation exchange or anion exchange.
• the present invention also includes all salts of the compounds of formula I which, because of low physiologically tolerability, are not directly suitable for use in pharmaceuticals but are suitable, for example, as intermediates for carrying out further chemical modifications of the compounds of formula I or as starting materials for the preparation of physiologically tolerable salts.
• a further aspect of the invention is the use of a compound of the formula I as prepared by the process according to the invention for the production of pharmaceuticals, diagnostic agents, liquid crystals, polymers, herbicides, fungicidals, nematicidals, parasiticides, insecticides, acaricides and arthropodicides.
• the compounds of the formula I can be used as synthesis intermediates for the preparation of other compounds, in particular of other pharmaceutical active ingredients, which are obtainable from the compounds of the formula I, for example by introduction of substituents or modification of functional groups.
• an acid such as trifluoroacetic acid or acetic acid was used, for example when trifluoroacetic acid was employed to remove a tBu group or when a compound was purified by chromatography using an eluent which contained such an acid, in some cases, depending on the work-up procedure, for example the details of a freeze-drying process, the compound was obtained partially or completely in the form of a salt of the acid used, for example in the form of the acetic acid salt or trifluoroacetic acid salt or hydrochloric acid salt.
• the organic phase was dried over Na 2 SO 4 followed by filtration, or by filtering through a Varian cartridge Chem Elut 12198007, before the solvent was removed by rotary evaporation and the residue purified by flash chromatography on silica using CH 2 CI 2 /heptane/Et0Ac mixtures. After removal of the organic solvents by rotary evaporation the desired N-aminoindole was obtained in high purity.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
• Indole Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=38457866

Family Applications (1)

Country Status (12)

Cited By (38)

Families Citing this family (6)

Citations (3)

Family Cites Families (2)

• 2008
  • 2008-03-29 WO PCT/EP2008/002519 patent/WO2008125207A1/en not_active Ceased
  • 2008-03-29 AU AU2008238379A patent/AU2008238379A1/en not_active Abandoned
  • 2008-03-29 BR BRPI0810199-0A2A patent/BRPI0810199A2/pt not_active IP Right Cessation
  • 2008-03-29 KR KR1020097021379A patent/KR20100015546A/ko not_active Withdrawn
  • 2008-03-29 CA CA002683578A patent/CA2683578A1/en not_active Abandoned
  • 2008-03-29 AT AT08734883T patent/ATE537142T1/de active
  • 2008-03-29 CN CN200880011689A patent/CN101657422A/zh active Pending
  • 2008-03-29 MX MX2009010536A patent/MX2009010536A/es active IP Right Grant
  • 2008-03-29 JP JP2010502442A patent/JP5412422B2/ja not_active Expired - Fee Related
  • 2008-03-29 EP EP08734883A patent/EP2134682B1/en not_active Not-in-force
• 2009
  • 2009-09-30 IL IL201253A patent/IL201253A0/en unknown
  • 2009-10-09 US US12/576,339 patent/US8026375B2/en not_active Expired - Fee Related

Patent Citations (3)

Non-Patent Citations (13)

Also Published As

Similar Documents

Legal Events